AstraZeneca, Daiichi post early win in Phase 3 trial for breast cancer therapy
(Source: Reuters: Health)
Source: Reuters: Health - September 22, 2023 Category: Consumer Health News Source Type: news
Episode 4: New Metastatic Castrate-Resistant Prostate Cancer Therapies Episode 4: New Metastatic Castrate-Resistant Prostate Cancer Therapies
Drs Sandhya Srinivas and Oliver Sartor discuss the VISION study, new therapies for patients with metastatic castrate-resistant prostate cancer, and PSMA biomarker-based imaging.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
‘Theory of all matter’ physicists among 2023 Breakthrough prize winners
Immunologists behind pioneering cancer therapy also among recipients of most lucrative prize in scienceTwo physicists who played a key role in advancing a theory that describes the basis of all matter and a pair of immunologists who developed a pioneering cancer therapy that is currently being investigated as a treatment for autoimmune disease are among the winners of the most lucrative prize in science.Founded in 2012, the Breakthrough prize is the world ’s largest international science prize, with the winners of the five main awards – three in life sciences, one in fundamental physics, and one in mathematics – each...
Source: Guardian Unlimited Science - September 14, 2023 Category: Science Authors: Linda Geddes Science correspondent Tags: Science prizes Medical research Cancer Physics Source Type: news
2024 Breakthrough Prizes in Life Sciences
This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease. (Source: The Scientist)
Source: The Scientist - September 14, 2023 Category: Science Tags: News News & Opinion Source Type: news
ASTRO president speaks at cancer panel
Jeff Michalski, MD, president of the American Society for Radiation Oncolog...Read more on AuntMinnie.comRelated Reading:
ASTRO names new board officers, awards fellowships
ASTRO urges discussion with Congress about staff shortages
ASTRO, ESTRO issue guidelines for lung cancer therapy
ASTRO: Radiation oncology workforce appears stable
ACR, ASTRO cry foul over imaging cuts in 2023 Omnibus bill (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 7, 2023 Category: Radiology Source Type: news
AHN Opens New Precision Medicine and Developmental Therapeutics Cancer Clinic at AGH
Leading Medical Oncologist Dr. Ariel Lopez-Chavez Recruited to Direct Program That Will Develop the Next Generation of Tailored Cancer Therapies PITTSBURGH, Sept. 7, 2023 /PRNewswire-PRWeb/ -- The Allegheny Health Network Cancer Institute (AHNCI) announced today that it has established... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 7, 2023 Category: Pharmaceuticals Tags: PER PDT Source Type: news
First-in-class targeted microRNA therapy slows cancer tumor growth
A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported in Oncogene, tumors treated with the new therapy did not increase in size over the course of a 21-day study, while untreated tumors tripled in size over the same time period.
Cancer can begin almost anywhere in the human body. It is characterized by cells that divide uncontrollably and that may be able to ignore signals to die or stop dividing, and even evade the immune system. (Source: World Pharma News)
Source: World Pharma News - September 5, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
How Unique Immune Cells can Recognize - and destroy - Tumors
Gamma delta T cells, a special type of cell in the immune system, are incredibly effective at recognizing and killing cancer cells. Cancer patients with higher levels of these T cells in their tumors tend to fare better than those with lower levels. But scientists have struggled to understand exactly how gamma delta T cells can recognize cancerous cells, and how new cancer therapies may be able to take advantage of these powerful immune cells. (Source: World Pharma News)
Source: World Pharma News - August 31, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Financial Toxicity Screening Can Reduce Cancer Cost Burdens Financial Toxicity Screening Can Reduce Cancer Cost Burdens
Including routine screening for financial toxicity as part of regular patient monitoring can mitigate financial difficulties among patients undergoing systemic cancer therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
Cancer Therapy's Lower-Limb Blood Clots Better Treated With Long Anticoagulation
(MedPage Today) -- AMSTERDAM -- A prolonged course of edoxaban (Savaysa) was more effective for isolated distal deep vein thrombosis in cancer patients, the ONCO DVT randomized trial showed.
By 12 months, symptomatic recurrent venous thromboembolism... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 29, 2023 Category: Cardiology Source Type: news
CLS Americas inks partnership with Focalyx
Clinical Laserthermia Systems (CLS) Americas has inked a comarketing agreemen...Read more on AuntMinnie.comRelated Reading:
CLS Americas receives first thermal therapy system order
First patient treated with CLS prostate cancer therapy system (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 28, 2023 Category: Radiology Source Type: news
Lab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatment
This week's Lab Notes has items on a gastric cancer discovery, a bio-manufacturing deal, a positive update on an experimental cancer therapy and more. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 25, 2023 Category: Pharmaceuticals Authors: John George Source Type: news
Fore Biotherapeutics raises $75M to advance potential cancer therapy, announces CEO departure
Philadelphia-based Fore Biotherapeutics has now raised $166 million in funding. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 23, 2023 Category: Biotechnology Authors: John George Source Type: news
